Compare WILC & SIGA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WILC | SIGA |
|---|---|---|
| Founded | 1994 | 1995 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.5M | 421.8M |
| IPO Year | 1997 | 1997 |
| Metric | WILC | SIGA |
|---|---|---|
| Price | $27.59 | $6.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 17.6K | ★ 374.9K |
| Earning Date | 11-17-2025 | 11-06-2025 |
| Dividend Yield | 3.04% | ★ 9.29% |
| EPS Growth | ★ 64.86 | N/A |
| EPS | ★ 2.05 | 1.03 |
| Revenue | ★ $180,746,882.00 | $172,249,641.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $132.36 |
| P/E Ratio | $13.48 | ★ $6.27 |
| Revenue Growth | ★ 4.22 | N/A |
| 52 Week Low | $12.54 | $4.95 |
| 52 Week High | $27.98 | $9.62 |
| Indicator | WILC | SIGA |
|---|---|---|
| Relative Strength Index (RSI) | 74.98 | 45.74 |
| Support Level | $27.56 | $6.13 |
| Resistance Level | $27.98 | $6.55 |
| Average True Range (ATR) | 0.47 | 0.20 |
| MACD | 0.14 | 0.13 |
| Stochastic Oscillator | 89.18 | 74.31 |
G. Willi-Food International Ltd is a company engaged in high-quality, great-tasting kosher food products. The Company is engaged, directly and through subsidiaries, with one segment Import-export, marketing, and distribution of food products. The principal product line includes Canned Vegetables and Pickles, Canned Fish, Canned Fruit, Edible Oils, Dairy and Dairy Substitute Products, Dried Fruit, Nuts and Beans, and Other Products. Its brands include Willi-Food, Euro European Dairies, Donna Rozza, Manchow, Gold Frost, Tifeeret, The Chef Dish, Art Coffe, Mr. Chang, Muchi, Euro Butter, Euro Spread, Euro Cheese, Euro Cream, Euro Dessert, Euro Veg, Ha-Bulgaria, Gelato, and Emma.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.